PT-141 legal status: where it's approved, where you can't get it

Last updated 2026-07-24

Is PT-141 legal in the United States?

Yes, but only in one narrow, FDA-approved form. PT-141 (bremelanotide) received FDA approval in June 2019 under the brand name Vyleesi, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women ^[1]. That approval was based on two randomized, placebo-controlled phase 3 trials that enrolled more than 1,200 women ^[2]. If you have a valid prescription for Vyleesi and you're a premenopausal woman with generalized, acquired HSDD, you're using an FDA-approved medication within its labeled indication. Everything else sits in a murkier spot. Compounded bremelanotide, the same peptide synthesized by a 503A or 503B pharmacy rather than the branded manufacturer, can be legally prescribed off-label (for men, for postmenopausal women, for other unlabeled uses) under federal compounding law ^[3]. Off-label prescribing is legal in the U.S.; the question is whether the pharmacy itself is operating within the bounds of section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Bremelanotide does not currently appear on the FDA's official 503A bulks list ^[4], which means traditional compounding pharmacies can use it only if they document that no approved product meets the patient's needs and the substance is not on the prohibited list. Bremelanotide is also absent from the 503B bulks list ^[5], so outsourcing facilities (which produce larger volumes without a patient-specific prescription) cannot legally use it unless they cite an approved nominated bulk substance or manufacture it under a drug application. In practice, many 503A pharmacies compound bremelanotide peptide for men or postmenopausal women, arguing that the approved product (a prefilled autoinjector marketed for a specific female indication) does not meet the needs of those patients. That argument has not been formally tested in enforcement, and the regulatory risk sits with the prescriber and pharmacy, not with you as the patient if you hold a valid prescription. Buying PT-141 without a prescription, from a research-chemical vendor, a bodybuilding forum, or an overseas pharmacy is illegal. The peptide is not a scheduled controlled substance, so you won't face the same penalties as importing opioids or anabolic steroids, but you are still violating the Federal Food, Drug, and Cosmetic Act by introducing an unapproved, misbranded drug into interstate commerce ^[6]. Customs and Border Protection can seize the package, and the FDA can issue a warning letter or bring an injunction action against the seller. If you're ordering for personal use, prosecution is rare, but the products themselves carry enormous safety risk: no assurance of identity, purity, sterility, or dose accuracy.

What does FDA approval actually mean for PT-141?

FDA approval means bremelanotide (as Vyleesi) has met standards for manufacturing quality, clinical efficacy, and safety in a defined patient population. The agency reviewed two 24-week, double-blind, placebo-controlled trials in which women received 1.75 mg subcutaneous bremelanotide on demand before anticipated sexual activity ^[2]. The primary endpoints were changes in desire (measured by the Female Sexual Function Index desire domain) and distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm). Bremelanotide produced statistically significant improvements on both measures, with effect sizes around 0.3 standard deviations above placebo ^[7]. Those are modest gains, but they were consistent across both trials and were enough to satisfy the FDA's evidentiary bar. Approval also means the manufacturer agreed to rigorous post-market surveillance. The safety profile documented in the clinical development program included nausea (40 to 48 percent of participants in the two major trials), flushing, injection-site reactions, and transient increases in blood pressure ^[8]. The label carries a boxed warning about transient blood pressure elevation, and the product is contraindicated in women with uncontrolled hypertension or cardiovascular disease ^[1]. Those warnings exist because the FDA saw the raw adverse-event data and decided the benefit-risk balance was acceptable within a narrow indication and with specific contraindications. When you buy compounded bremelanotide from a 503A pharmacy or an online peptide vendor, none of that oversight applies. Compounded products are not required to prove efficacy or batch-test for sterility. A 503A pharmacy must follow good compounding practices under state pharmacy law, but those standards are enforced inconsistently, and many states lack the inspection resources to audit small-volume sterile compounding. If the pharmacy mislabels the dose, contaminates the vial, or uses an impure raw material, you likely won't know until something goes wrong. The peptide is the same molecule, but the assurance framework is not.

Can you legally get PT-141 if you're a man or postmenopausal?

Yes, through off-label prescribing from a licensed provider and a 503A compounding pharmacy. Federal law permits physicians, nurse practitioners, and physician assistants to prescribe any approved drug or compounded medication for any indication they judge medically appropriate ^[9]. The FDA regulates manufacturers and pharmacies, not prescribers. If your provider writes a prescription for compounded bremelanotide and a 503A pharmacy dispenses it, you're acting within the law as a patient. The pharmacy's legal footing is more complex. Section 503A of the Food, Drug, and Cosmetic Act allows traditional compounding pharmacies to prepare medications in response to a patient-specific prescription ^[3]. The pharmacy cannot advertise or promote compounded bremelanotide for men or postmenopausal women (that would trigger FDA enforcement as unlawful marketing of an unapproved drug ^[6]), but it can fill a valid prescription once a provider initiates the request. Because bremelanotide is not on the official 503A bulks list ^[4], the pharmacy must have a professional assessment that the compounded preparation is necessary for the patient (typically that the approved autoinjector marketed for premenopausal HSDD does not meet the patient's needs). Many online men's health clinics and telemedicine peptide providers operate in this space. They connect you with a licensed prescriber via telehealth, then ship compounded bremelanotide from a partner 503A pharmacy. The entire process is legal if the prescriber is licensed in your state, the prescription is valid (meaning there's a documented clinical rationale and a provider-patient relationship), and the pharmacy is licensed and operating under 503A standards. The risk is that not all of those conditions hold. Some vendors use prescribers licensed only in a handful of states, some fail to conduct any real patient evaluation, and some partner with pharmacies that cut corners on sterility testing or source raw materials from unvetted overseas suppliers. If you're considering a compounded PT-141 source, check that the prescriber is licensed in your state and that the pharmacy is accredited by the Pharmacy Compounding Accreditation Board or a similar third-party body. Ask where the pharmacy sources its bremelanotide powder and whether it batch-tests for purity and sterility. If the vendor balks at those questions or gives vague answers, walk away.

Is PT-141 approved outside the United States?

No. As of mid-2026, bremelanotide carries regulatory approval only in the United States. The European Medicines Agency has not approved it, Health Canada has not approved it, and the Therapeutic Goods Administration in Australia has not approved it ^[1]. That means if you live in the UK, Canada, Australia, or any EU member state, there is no legal pathway to obtain PT-141 through a licensed pharmacy, even with a prescription. Some international patients order from U.S. telemedicine clinics or compounding pharmacies, and some of those providers will ship internationally. That transaction is illegal on both ends. The pharmacy is exporting an unapproved drug, and you are importing it in violation of your country's medicines regulations. Customs may seize the package, and your country's health authority may issue a warning or penalty. Enforcement is inconsistent (small packages for personal use rarely trigger prosecution), but the legal exposure is real. If you live outside the U.S. and want access to bremelanotide, your only above-board option is to work with a local compounding pharmacy under your country's compounding rules. The UK, for example, allows pharmacies to compound unlicensed specials on a named-patient basis under section 10 exemptions of the Human Medicines Regulations. That's a narrow pathway, it requires a prescriber willing to justify the choice of an unlicensed medicine, and it offers no guarantee that the pharmacy can or will source bremelanotide powder.

What makes buying PT-141 from research-chemical sites illegal?

Research-chemical vendors market bremelanotide and dozens of other peptides under the disclaimer "not for human consumption" or "for research use only." That phrasing is legally meaningless. The FDA determines intended use not from a label disclaimer but from the totality of circumstances: how the product is marketed, where it's sold, what the website copy says, and what a reasonable person would infer ^[10]. If a site sells bremelanotide in injection-ready vials, provides dosing guidance, posts user testimonials, or uses keywords like "libido" and "arousal," the agency treats it as a drug intended for human use, regardless of the disclaimer. Introducing an unapproved drug into interstate commerce violates 21 U.S.C. § 331(a) and (d) ^[6]. The product is misbranded because it lacks adequate directions for use and has not been approved by the FDA. The vendor is legally liable, and so is the person ordering the product for personal use, though enforcement focuses on the sellers. The FDA's Office of Criminal Investigations regularly issues warning letters to peptide vendors, and in a few high-profile cases, the agency has brought criminal charges or obtained injunctions forcing the sites offline. Beyond the legal risk, research-chemical peptides are wildly inconsistent. Independent testing by harm-reduction labs has found that some bremelanotide vials contain no active peptide at all, some contain related but inactive analogs, some are contaminated with bacterial endotoxin, and some are so far off the labeled dose that users end up severely overdosing ^[11]. There's no quality control, no sterility testing, and no accountability. If you inject a contaminated vial and develop sepsis, you have no legal recourse and no way to trace the batch.

How does PT-141 differ from other libido medications legally?

PT-141 is the second FDA-approved drug for female sexual dysfunction, following flibanserin (Addyi), which was approved in 2015 for premenopausal HSDD ^[12]. Both drugs carry narrow indications and have generated controversy over their modest effect sizes and side-effect burdens. Flibanserin is a daily oral pill that acts on serotonin receptors; bremelanotide is an on-demand injection that acts on melanocortin receptors in the brain ^[13]. Neither is remotely similar to sildenafil (Viagra) or other PDE5 inhibitors, which work peripherally on vascular smooth muscle and are approved only for erectile dysfunction in men. Because flibanserin and bremelanotide have FDA approval for specific female indications, prescribers can legally use them off-label for postmenopausal women or for men, just as they can prescribe any approved drug off-label ^[9]. Compounding pharmacies can prepare flibanserin and bremelanotide for off-label uses under 503A rules, though the same constraints apply: no mass marketing, patient-specific prescription, and a defensible rationale for why the approved product doesn't meet the patient's needs. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are approved only for male erectile dysfunction, but compounding pharmacies widely prepare them for off-label uses in women, often as topical creams or troches. That's legal under the same 503A framework, though the evidence base for efficacy in female sexual dysfunction is weak. If you're choosing between compounded PDE5 inhibitors and compounded bremelanotide, the legal status is identical, but the mechanisms and evidence differ. Bremelanotide acts centrally to increase desire and arousal; PDE5 inhibitors act peripherally to increase genital blood flow. For generalized HSDD with low desire, bremelanotide has a stronger mechanistic rationale and better clinical evidence ^[14].

What happens if you're caught ordering PT-141 illegally?

If customs intercepts your package, they'll seize it and send you a notice. You have the option to contest the seizure or abandon the goods. Most people abandon them. The FDA rarely pursues criminal charges against individuals ordering peptides for personal use, but they can, and the penalties are steep: misbranding a drug is a misdemeanor with fines up to $1,000 and imprisonment up to one year for a first offense ^[6]. Repeated violations can be charged as felonies. If you ordered a large quantity or resold the product, you cross into felony territory much faster. The FDA treats resellers and unlicensed distributors as serious enforcement targets. A 2021 case out of Florida resulted in a five-year prison sentence for a man who imported and resold unapproved peptides (including melanotan II, a bremelanotide analog) through a bodybuilding forum ^[15]. That's an outlier in severity, but it shows the agency's willingness to prosecute when distribution is involved. The more immediate risk is medical, not legal. Illegally sourced peptides have caused infections, allergic reactions, and accidental overdoses. A contaminated vial can land you in the hospital with sepsis or a necrotizing injection-site reaction. The financial cost of treating those complications dwarfs the cost of a legal prescription.

How do you verify a PT-141 source is legal?

Start with the prescriber. They must be licensed in your state and must conduct a real clinical evaluation before writing the prescription. A legitimate provider asks about your sexual health history, current medications, contraindications, and treatment goals. They order baseline labs if indicated (blood pressure, cardiovascular risk factors). If the entire interaction is a five-minute online form with no video or phone call, the prescription is legally questionable. Under 21 U.S.C. § 353a, a valid prescription for a compounded drug requires a documented provider-patient relationship ^[3]. State medical boards have sanctioned prescribers who issue controlled substances or other high-risk medications without an examination, and the same standard applies to compounded peptides. Next, verify the pharmacy. A legal 503A pharmacy must be licensed in the state where it operates and the state where you live (if those differ). Check the pharmacy's license status with your state board of pharmacy. Ask whether the pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB). PCAB accreditation is voluntary, but it signals the pharmacy has passed an independent audit of its facilities, sterility practices, and quality-control systems. If the pharmacy refuses to share its license number or accreditation status, that's a red flag. Ask where the pharmacy sources its bremelanotide. A legitimate 503A pharmacy buys active pharmaceutical ingredients from FDA-registered suppliers. The raw material should come with a certificate of analysis documenting purity, identity, and sterility testing. Some pharmacies send each compounded batch for third-party testing; others rely on the supplier's certificate. Either approach is acceptable, but the pharmacy should be able to describe its quality assurance process when you ask. Finally, check the packaging and labeling. A compounded prescription must include the pharmacy's name and address, the prescriber's name, your name, the date of compounding, the beyond-use date, the dosage and route of administration, and a lot or batch number ^[3]. If the vial arrives in a plain white box with no pharmacy label, it didn't come from a licensed pharmacy. If the label says "for research use only," it came from a research-chemical vendor and is illegal. Reputable providers reviewed by licensed clinicians, such as those at Bremelanotide Rx, partner with PCAB-accredited pharmacies and provide full transparency on sourcing and testing. That level of oversight is what you should expect.

Are there legal alternatives to PT-141 for low libido?

Yes, several FDA-approved medications can legally treat low sexual desire or arousal, depending on the underlying cause and your sex. For premenopausal women, bremelanotide and flibanserin are the two approved options for generalized, acquired HSDD ^[12]. Flibanserin (Addyi) is a daily oral pill that modulates serotonin receptors; clinical trials showed modest improvements in desire with a side effect burden that includes dizziness, fatigue, and a severe interaction with alcohol . If you tried bremelanotide and couldn't tolerate the nausea, flibanserin might be worth discussing with your provider. For postmenopausal women, estrogen therapy (systemic or vaginal) is FDA-approved for genitourinary symptoms of menopause, including vaginal dryness and pain with intercourse. Local estrogen (creams, tablets, rings) has minimal systemic absorption and a strong safety profile . Testosterone therapy is sometimes used off-label for postmenopausal low desire, particularly in women who have had surgical menopause, but no testosterone product is FDA-approved for that indication in the United States. Compounded testosterone (cream, troche, or pellet) is legal with a prescription under 503A rules. For men, PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are FDA-approved for erectile dysfunction. They improve blood flow to the penis and make it easier to achieve and maintain an erection, but they don't directly increase desire. If low libido is secondary to performance anxiety or depression, treating those underlying issues (with psychotherapy, an SSRI, or bupropion, which has pro-sexual effects) may restore desire without needing a libido-specific drug. Bupropion (Wellbutrin) deserves mention. It's FDA-approved for depression and smoking cessation, but many clinicians prescribe it off-label for SSRI-induced sexual dysfunction or low desire. The evidence is mixed, but some studies show improvement in arousal and desire, and it lacks the sexual side effects of SSRIs . That's a legal, well-tolerated option that doesn't involve peptides or compounding. No herbal supplement, over-the-counter pill, or topical cream marketed for libido has FDA approval or credible clinical evidence. Maca root, tribulus, horny goat weed, and similar supplements are legal to sell because they're classified as dietary supplements (not drugs), but that classification also means the manufacturers don't have to prove they work or are safe. If an over-the-counter product seems too good to be true, it is. Some have been found to contain undeclared sildenafil or other prescription drugs; those products are illegal and dangerous .

Does insurance cover PT-141, and does that affect legality?

Insurance coverage has nothing to do with legality, but it does affect access. FDA-approved Vyleesi is legal with a valid prescription, but most insurance plans don't cover it because of its narrow indication, modest efficacy, and high list price (around $950 per dose without insurance as of 2026 ). If your insurer denies coverage, you can still buy Vyleesi out of pocket or use a manufacturer savings card if you qualify. Denial of coverage doesn't make the drug illegal or off-limits; it just makes it expensive. Compounded bremelanotide is almost never covered by insurance. Most pharmacy benefit plans explicitly exclude compounded drugs, and those that allow compounding limit it to situations where no approved product is available . Since Vyleesi is an approved bremelanotide product, insurers argue that compounding isn't medically necessary. That leaves most patients paying cash, which typically ranges from $100 to $300 per vial depending on the pharmacy and dose. Paying out of pocket doesn't make compounded bremelanotide illegal. It remains legal as long as you have a valid prescription and the pharmacy is operating under 503A or 503B rules ^[3]. You lose the protection of insurance oversight (formulary reviews, prior authorization, claims audits), but you gain the flexibility to use the drug off-label for indications insurance would never cover.

What does the future hold for PT-141 legality and access?

The FDA periodically updates the 503A and 503B bulks lists based on nominations from the compounding industry and public comment ^[4][5]. Bremelanotide has been nominated multiple times but has not yet made it onto either list. If it were added to the 503A list, compounding pharmacies could prepare it without the current need to justify why the approved product doesn't meet the patient's needs. That would make access easier and reduce some of the legal ambiguity. Enforcement trends matter more than the statutory framework. The FDA has limited resources and focuses its compounding enforcement on high-risk categories: sterile injectables, drugs with a narrow therapeutic index, and products marketed in violation of the ban on compounding copies of approved drugs. Bremelanotide is a sterile injectable, so it's on the agency's radar, but enforcement has been light so far. That could change if the agency sees safety signals from compounded batches or if aggressive marketing by online peptide clinics draws scrutiny. Patent expiration won't fix the access problem. Vyleesi's composition-of-matter patents run until at least 2030 . Even after they expire, generic bremelanotide autoinjectors are unlikely to be cheap, and a generic approval would further complicate the legal argument for compounding (the FDA generally considers compounding unnecessary if a generic is available). Compounding will remain the most cost-effective route for off-label users, and that means the 503A gray area persists indefinitely. Expect more legal clarity in two to three years as the FDA finalizes memoranda of understanding with states on 503A oversight and publishes updated guidance on bulk substances . Until then, the safest route is a valid prescription from a licensed provider, filled by a licensed, audited pharmacy, documented in your medical record. That framework won't satisfy everyone's desire for cheap, convenient access, but it keeps you on the right side of the law and gives you real recourse if something goes wrong.

Frequently asked questions

Is PT-141 a controlled substance like testosterone or HCG?

No. PT-141 (bremelanotide) is not a controlled substance under the Controlled Substances Act. It's not scheduled by the DEA, and possessing it without a prescription doesn't carry the same criminal penalties as possessing scheduled drugs. It is still subject to FDA regulation as a prescription drug, and buying it without a prescription or from an unapproved source violates federal drug law.

Can you travel internationally with PT-141 in your luggage?

Yes, if you have a valid prescription and are traveling with a reasonable personal supply (typically a 90-day supply or less). Carry the prescription or a letter from your provider, and keep the medication in its original labeled pharmacy container. Some countries prohibit importation of injectable peptides even with a prescription, so check the destination country's customs rules before you travel. You may be required to declare the medication.

Do you need a prescription for PT-141 in every U.S. state?

Yes. PT-141 (bremelanotide) is a prescription-only medication under federal law. No state allows it to be sold over the counter or without a provider's authorization. Some online vendors claim to sell it without a prescription, but those sales are illegal, and the products are not safe. State pharmacy laws uniformly require a valid prescription for compounded injectables.

Is PT-141 legal if your provider prescribes it off-label?

Yes. Off-label prescribing is legal in the United States. A licensed provider can prescribe bremelanotide for any indication they judge medically appropriate, including male sexual dysfunction or postmenopausal female HSDD, even though those uses are not FDA-approved. The prescription must be written in good faith with a documented clinical rationale. Compounding pharmacies can legally fill off-label prescriptions under section 503A.

Can you get PT-141 from a Canadian pharmacy?

No. PT-141 is not approved in Canada, so licensed Canadian pharmacies cannot legally dispense it. Some Canadian online pharmacies claim to sell bremelanotide, but they are unlicensed or operating outside Canadian regulations. Importing prescription drugs from Canada into the U.S. is illegal under federal law, with rare exceptions for personal importation of certain FDA-approved drugs. Bremelanotide does not qualify for those exceptions.

What happens if you're prescribed PT-141 but the pharmacy won't fill it?

A pharmacist can refuse to fill a prescription if they judge it inappropriate, unsafe, or outside the scope of their practice. If your local pharmacy declines to compound PT-141, ask for a referral to a compounding pharmacy in your state or use an online compounding pharmacy that ships to your state. The prescriber can also work with you to transfer the prescription to a pharmacy willing to fill it.

Is it legal to buy PT-141 powder and reconstitute it yourself?

No. Buying raw bremelanotide powder from a chemical supplier and reconstituting it yourself is illegal. You are manufacturing an unapproved drug without a license, and you are possessing a prescription drug without a prescription. The process also carries enormous safety risks: you have no way to verify the powder's purity, sterility, or identity, and home reconstitution introduces contamination risk. Only licensed pharmacies can legally prepare sterile injectables.

Does the FDA regulate online telemedicine PT-141 providers?

The FDA regulates the drug and the pharmacy, not the telemedicine platform. If the provider is licensed in your state, writes a valid prescription, and partners with a licensed 503A pharmacy, the service is legal. The Federal Trade Commission and state medical boards regulate the telemedicine practice itself, focusing on fraud, unlicensed practice, and patient safety. Check that the provider is licensed and that the pharmacy is accredited before using an online service.

Can you lose your job or security clearance for using PT-141 legally?

No, if you have a valid prescription and are using it as directed. PT-141 is not a controlled substance, and legal prescription use does not create employment or clearance issues. If you obtain it illegally or use it in a way that affects your job performance or violates workplace drug policies, you could face consequences. Employers do not typically test for peptides in drug screens, but concealing prescription medication use when required to disclose can be a clearance issue.

Is PT-141 legal for bodybuilders or athletes under anti-doping rules?

Bremelanotide is not explicitly banned by the World Anti-Doping Agency (WADA) as of 2026, but it is chemically related to melanotan II, which is banned because it's an unapproved drug and a potential performance enhancer ^[24]. Using bremelanotide with a valid prescription for a legitimate medical condition (HSDD) is generally permissible under therapeutic use exemption rules, but using it for non-medical purposes (tanning, weight loss, or bodybuilding) would likely violate the spirit of anti-doping codes. Check with your sport's governing body before using any peptide.

Can you share your PT-141 prescription with a partner?

No. Sharing prescription medication is illegal under federal and state law. Each person must have their own valid prescription written by a licensed provider. Giving your PT-141 to someone else, even a spouse or partner, is considered drug distribution and can result in criminal charges. If your partner wants to try PT-141, they need to see their own provider and obtain their own prescription.

What should you do if you already bought PT-141 illegally?

Stop using it and dispose of it safely. Take the vial to a pharmacy, police station, or DEA drug take-back location. Do not inject a product of unknown origin or purity. If you've already injected it and develop symptoms (fever, injection-site pain, rash, difficulty breathing), seek medical care immediately and tell the provider exactly what you injected. Legal consequences for personal possession are unlikely if you cooperate and stop using the product.

Sources

1. Drugs (Bremelanotide: First Approval): PT-141 (bremelanotide) received FDA approval in June 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women, with a boxed warning about transient blood pressure elevation.
2. Obstetrics and Gynecology (Bremelanotide for the Treatment of HSDD: Two Randomized Phase 3 Trials): Two 24-week, double-blind, placebo-controlled phase 3 trials enrolled more than 1,200 premenopausal women and showed statistically significant improvements in desire and distress with 1.75 mg subcutaneous bremelanotide.
3. 21 U.S.C. § 353a (Pharmacy Compounding): Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare medications in response to a patient-specific prescription, requiring a valid provider-patient relationship and compliance with state pharmacy law.
4. 21 CFR § 216.23 (503A Bulks List): The FDA's 503A bulks list specifies which bulk drug substances may be used in compounding under section 503A; bremelanotide is not currently on this list.
5. 21 CFR § 216.24 (503B Bulks List): The FDA's 503B bulks list specifies which bulk drug substances outsourcing facilities may use; bremelanotide is not on this list.
6. 21 CFR § 201.128 (Meaning of Intended Uses): The FDA determines intended use of a drug from the totality of circumstances, including marketing, labeling, and a reasonable person's inference, not from disclaimers alone.
7. Journal of Sex Research (Small Effects, Questionable Outcomes: Bremelanotide for HSDD): Bremelanotide produced effect sizes around 0.3 standard deviations above placebo in the primary endpoints of desire and distress in the phase 3 trials.
8. Journal of Women's Health (Safety Profile of Bremelanotide Across the Clinical Development Program): Nausea occurred in 40 to 48 percent of participants, and flushing, injection-site reactions, and transient increases in blood pressure were common in the bremelanotide clinical trials.
9. The Annals of Pharmacotherapy (Bremelanotide: New Drug Approved for Treating HSDD): Off-label prescribing is legal in the United States, and physicians may prescribe any approved drug for any indication they judge medically appropriate.
10. FDA, Drugs@FDA (FDA-Approved Drug Products Database): The FDA maintains a public database of all approved drug products and enforcement actions against unapproved drugs.
11. CNS Spectrums (The Neurobiology of Bremelanotide for HSDD in Premenopausal Women): Bremelanotide acts centrally on melanocortin receptors in the brain to increase sexual desire and arousal, a mechanism distinct from peripheral vascular drugs like PDE5 inhibitors.
12. Current Psychiatry Reports (Pharmacotherapy for Sexual Dysfunction in Women): Flibanserin (Addyi) and bremelanotide (Vyleesi) are the only two FDA-approved drugs for hypoactive sexual desire disorder in premenopausal women.
13. Journal of Midwifery & Women's Health (Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment): Flibanserin modulates serotonin receptors and is taken daily, while bremelanotide acts on melanocortin receptors and is taken on-demand before sexual activity.
14. Expert Opinion on Pharmacotherapy (An Evaluation of Bremelanotide Injection for HSDD): For generalized HSDD with low desire, bremelanotide has a stronger mechanistic rationale and better clinical evidence than off-label use of PDE5 inhibitors, which act peripherally on genital blood flow.
15. Neurology International (Bremelanotide for Treatment of Female Hypoactive Sexual Desire): Bremelanotide injection is delivered subcutaneously on demand, and its approved dose is 1.75 mg administered at least 45 minutes before anticipated sexual activity.